In its latest quarterly filing for Q3 FY2026, ResMed demonstrated continued revenue growth and margin expansion driven by its integrated medical device and cloud-based software platform for respiratory health management. The departure of longtime CFO Brett Sandercock is offset by a structured succession plan, reflecting management stability. ResMed’s competitive moat remains anchored in its broad product portfolio and leading market position, with growth catalyzed by innovation, geographic expansion, and SaaS adoption. Robust liquidity and a strong balance sheet position the company well for ongoing investments despite regulatory and supply chain risks.